53 related articles for article (PubMed ID: 16517413)
1. Neuroblastoma Origin and Therapeutic Targets for Immunotherapy.
Kholodenko IV; Kalinovsky DV; Doronin II; Deyev SM; Kholodenko RV
J Immunol Res; 2018; 2018():7394268. PubMed ID: 30116755
[TBL] [Abstract][Full Text] [Related]
2. The Challenge of Developing New Therapies for Childhood Cancers.
Balis FM
Oncologist; 1997; 2(1):I-II. PubMed ID: 10388032
[TBL] [Abstract][Full Text] [Related]
3. Results of a Phase I study utilizing monocyte-derived dendritic cells pulsed with tumor RNA in children with Stage 4 neuroblastoma.
Caruso DA; Orme LM; Amor GM; Neale AM; Radcliff FJ; Downie P; Tang ML; Ashley DM
Cancer; 2005 Mar; 103(6):1280-91. PubMed ID: 15693021
[TBL] [Abstract][Full Text] [Related]
4. Characterization of CD34+ progenitor-derived dendritic cells pulsed with tumor cell lysate for a vaccination strategy in children with malignant solid tumors and a poor prognosis.
Ackermann B; Tröger A; Glouchkova L; Körholz D; Göbel U; Dilloo D
Klin Padiatr; 2004; 216(3):176-82. PubMed ID: 15175963
[TBL] [Abstract][Full Text] [Related]
5. The GD2-specific 14G2a monoclonal antibody induces apoptosis and enhances cytotoxicity of chemotherapeutic drugs in IMR-32 human neuroblastoma cells.
Kowalczyk A; Gil M; Horwacik I; Odrowaz Z; Kozbor D; Rokita H
Cancer Lett; 2009 Aug; 281(2):171-82. PubMed ID: 19339105
[TBL] [Abstract][Full Text] [Related]
6. [Immunotherapy of poor-prognosis neuroblastoma in children: from bench to bedside].
Rousseau R; Combaret V; Yvon E; Schell M; Philip I; Puisieux A; Frappaz D; Philip T; Bergeron C
Bull Cancer; 2006 Feb; 93(2):153-61. PubMed ID: 16517413
[TBL] [Abstract][Full Text] [Related]
7. Immunogenicity of human neuroblastoma.
Prigione I; Corrias MV; Airoldi I; Raffaghello L; Morandi F; Bocca P; Cocco C; Ferrone S; Pistoia V
Ann N Y Acad Sci; 2004 Dec; 1028():69-80. PubMed ID: 15650233
[TBL] [Abstract][Full Text] [Related]
8. Pharmacotherapy of neuroblastoma.
George RE; Diller L; Bernstein ML
Expert Opin Pharmacother; 2010 Jun; 11(9):1467-78. PubMed ID: 20408767
[TBL] [Abstract][Full Text] [Related]
9. Future aspects of immunotherapy and gene therapy in neuroblastoma.
Aktas S
J BUON; 2009 Sep; 14 Suppl 1():S175-9. PubMed ID: 19785063
[TBL] [Abstract][Full Text] [Related]
10. Disialoganglioside directed immunotherapy of neuroblastoma.
Modak S; Cheung NK
Cancer Invest; 2007 Feb; 25(1):67-77. PubMed ID: 17364560
[TBL] [Abstract][Full Text] [Related]
11. Immunotherapy of neuroblastoma: present, past and future.
Raffaghello L; Pistoia V
Expert Rev Neurother; 2006 Apr; 6(4):509-18. PubMed ID: 16623650
[TBL] [Abstract][Full Text] [Related]
12.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
13.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
14.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
15.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
16.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
17.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
18.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
19.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
20.
; ; . PubMed ID:
[No Abstract] [Full Text] [Related]
[Next] [New Search]
